一项新研究显示,巴里西提尼(Baricitinib)减慢了年轻病人1型糖尿病的发病速度,但在停止使用该药物后,其影响逆转。 A new study shows baricitinib slows type 1 diabetes progression in young patients, but effects reverse after stopping the drug.

一项新的研究发现,在10至30岁新诊断的病人中,用于风湿性关节炎和阿洛皮西亚的药丸巴里西蒂尼b可能会减缓1型糖尿病的发病速度。 A new study finds that baricitinib, a pill used for rheumatoid arthritis and alopecia, may slow type 1 diabetes progression in newly diagnosed patients aged 10 to 30. 经过48周的日常治疗后,与会者展示了保存的胰岛素生成乙型细胞功能、减少血糖波动和减少胰岛素需求。 After 48 weeks of daily treatment, participants showed preserved insulin-producing beta cell function, reduced blood sugar swings, and lower insulin needs. 然而,在停止使用该药物后,好处就消失了,血液糖控制和胰岛素使用率在96周前恢复到安慰剂水平。 However, benefits disappeared after stopping the drug, with blood sugar control and insulin use returning to placebo levels by week 96. 这种药物能平息过度活跃的免疫反应,它经过良好的授标和口服。 The drug, which calms overactive immune responses, was well-tolerated and taken orally. 研究人员说,研究结果对今后的试验很有希望,看长期或早期使用是否可以推迟或预防第1型糖尿病,如果规模较大的研究证实有效性,可能在五年内核准。 Researchers say results are promising for future trials to see if long-term or early use could delay or prevent type 1 diabetes, with potential approval within five years if larger studies confirm effectiveness. 调查结果是初步的,尚未经过同行审查。 Findings are preliminary and not yet peer-reviewed.